TRAW Traws Pharma, Inc.

BEARISH Impact: 7/10 EFFECT
Horizon weeks Filed May 18, 2026 Processed 26d 2h ago SEC 9999999995-26-001674
IPO/offering going effective
Latest settled — T+5d
TRAW ▼ -10.23% at T+5d
SHORT call ✓ call won +10.23% · α vs SPY +11.85% · entry $1.76 → $1.58
Next anchor: T+20d in 3d
Currently $1.28 · +27.27% from $1.76 entry (call sign-flipped)
Entry anchored
May 18, 2026
via day open
T+1d
-9.66%
call +9.66% · α +9.01%
$1.59
settled 25d ago
T+5d
-10.23%
call +10.23% · α +11.85%
$1.58
settled 18d ago
T+20d
call — · α —
in 3d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Traws Pharma's S-3 shelf registration (File No. 333-295727) became effective on May 15, 2026, enabling selling stockholders to resell up to 35,897,514 shares from an April 2026 private placement. The company receives no proceeds, and the audit report includes a going concern opinion, creating a massive potential overhang of 237% of current shares outstanding.

Actionable Insight

The effective shelf enables immediate selling by private placement holders, likely creating persistent downward pressure. Monitor for any takedown notices or Form 4 filings from selling stockholders. The going concern opinion amplifies risk — any sales could accelerate a death spiral.

Key Facts

  • S-3 shelf registration effective May 15, 2026, covering 35,897,514 shares for resale by selling stockholders
  • Company receives no proceeds from any sales under this shelf
  • Audit report includes a going concern opinion
  • Potential overhang equals approximately 237% of current shares outstanding
  • Stock trading below warrant exercise price, increasing dilution risk

Financial Impact

Potential dilution of 237% of current shares outstanding; no proceeds to company

dilutionshare price

Risk Factors

  • Massive dilution from up to 35.9M shares hitting the market
  • Going concern opinion signals potential insolvency risk
  • No cash inflow to offset dilution — pure overhang
  • Stock below warrant exercise price may trigger further dilution if warrants are exercised

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001674
Document: 9999999995-26-001674-index.html9999999995-26-001674
Document: 9999999995-26-001674.txt9999999995-26-001674
14 reports for TRAW
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+20▲ +42.15%Apr 15, 2026
Filters
Rows
Reports for TRAW — sortable, filterable
Type Now
Jun 12, 2026
today
8-K
BEARISH ★ 7/10
$1.29 awaiting T+5awaiting T+5$1.28 (+0.78%)
May 29, 2026
14d ago
DEFA14A
NEUTRAL ★ 3/10
$1.46 $1.45▼ −0.68%▼ −0.39%$1.28 (−12.33%)
May 27, 2026
16d ago
8-K
NEUTRAL ★ 4/10
$1.53 $1.42▼ −7.19%▼ −8.40%$1.28 (−16.34%)
May 26, 2026
17d ago
8-K
NEUTRAL ★ 3/10
$1.53 $1.45▼ −5.23%▼ −5.70%$1.28 (−16.34%)
May 22, 2026
22d ago
424B5
BEARISH ★ 7/10
$1.49 $1.47▲ +1.34%▲ +3.02%$1.28 (+14.09%)
May 18, 2026
26d ago
EFFECT
BEARISH ★ 7/10
$1.76 $1.58▲ +10.23%▲ +11.85%$1.28 (+27.27%)
May 15, 2026
29d ago
8-K
BEARISH ★ 7/10
$1.88 $1.49▲ +20.74%▲ +21.71%$1.28 (+31.91%)
May 15, 2026
29d ago
Press Release
MIXED ★ 5/10
$1.88 $1.49▼ −20.74%▼ −21.71%$1.28 (−31.91%)
May 8, 2026
5w ago
S-3
BEARISH ★ 8/10
$2.02 $1.76▲ +12.87%▲ +12.79%$1.28 (+36.63%)
May 8, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$2.18 $1.63▼ −25.23%▼ −26.69%$1.28 (−41.28%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (48h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access